The influence of paclitaxel on IL-36γmediated tumor suppression
LU Han-lin1, SONG Ying-ying1， SHEN Chun-ping1， CHEN Chen1， LIU Xiao-cao1, FENG Chao3,
LU Bin-feng1， ZHU Yi-bei1, SUN Zhong-wen2, WANG Xue-feng1
1. School of Biology and Basic Medical Sciences, Soochow University, Suzhou Jiangsu 215123; 2. School of Medicine and Technology, Suzhou Vocational Health College, Suzhou Jiangsu 215009; 3. Institutes for Translational Medicine, Soochow University, Suzhou Jiangsu 215123, China）
Abstract：Objective: To investigate the influence of paclitaxel on IL36γmediated antitumor effect at different doses. Methods: The transfect B16IL36γ, which can stably secret IL36γ protein,was established by transfecting the recombinant expression vector pCDEF3IL36γ into B16 cell line,selecting with G418, subcloning and validating using RTqPCR method.At the same time, the control B16vec was obtained.The characteristics of tumor expressedIL36γmediated tumor growth suppression was analyzed by constructing mouse tumor model with B16IL36γ as well as B16vec. The influence of paclitaxel on IL36γ mediatedtumor arrest was investigated through observing tumor growth and measuring the level of interferonγ(IFNγ) mRNA expression in tumors after paclitaxel was inoculated intraperitoneally at different doses(0,12.5,25 and 100 μg). Results: The transfected cell line B16IL36γ, which stably expressed IL36γ, was successfully obtained. Our findings showed that IL36γ could significantly inhibit the growth of B16 tumors.A higher dose of paclitaxel with 100 μg could significantly suppress IL36γmediated inhibition of tumor growth and IFNγ expression in tumor tissue.However,a lower dose of paclitaxel with 12.5 μg exerted a synergistic effect on inhibition of tumor growth and IFNγ mRNA expression. Conclusion: Lower dose of paclitaxel may be used to combine with cytokine IL-36γ in tumor immunotherapy for achieving a certain synergistic effect.
2018, Vol. 28 
